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Hie metabolic activation of the heterocyclk food carcinogen
2-amino-3-methylimidazo[4,5-/|quinolin€ (IQ) by two human
cytochrome P450 monooxygenases (P4501A1 and P4501A2)
and two human N-acetyltransferases (NAT1 and NAT2) was
investigated. Various combinations of these enzymes were
functionally expressed in COS-1 cells. DNA adducts resulting
from the activation of IQ were assayed quantitatively by the
32P-postlabeling procedure. The highest adduct frequency
was observed in cells expressing both CYP1A2 and NAT2.
CYP1A2 in combination with NAT1 was 3—6 times less
active. When expressed alone these enzymes gave rise to low
adduct frequencies. Experiments with iV-acetyl-IQ as
substrate suggest that NAT1 and NAT2 in addition to their
known role in Ar-acetyiation display arylhydroxamic acid N,O-
acetyttransferase (AHAT) activity. Quantitative differences
in adduct formation between IQ and A'-acetyl-IQ indicated
that metabolic activation of these arylamines preferentially
occurs by P4501A2-catalyzed W-hydroxylation followed by
O-acetylation mediated through NAT1 and/or NAT2. These
data, in combination with the known genetic polymorphism
of NAT2, may explain the clinical observation that the
acetylation polymorphism constitutes a risk factor in the
carcinogenic activation of environmental mutagens.
Introduction
Frying of meat and fish results in the generation of heterocyclic
arylamines (1), which present a major source of dietary
carcinogens. Among a number of food-derived heterocyclic
amines, 2-aiTuno-3-memylimidazo[4,5-/]quinoline (IQ*) was
found to be highly mutagenic in Salmonella typhimurium, and
its carcinogenic potential was demonstrated in various rodent
species and a primate (2,3).
The effects of heterocyclic arylamines, like those of other
arylamines, require metabolic activation by drug-metabolizing
enzymes. It is generally accepted that the ultimate mutagens/car-
cinogens are electrophilic arylnitrenium ions, which can react
with DNA and form adducts (4-6) . Reactions involved in the
metabolic activation include N-hydroxylation and N- and O-
acetylation (Figure 1), catalyzed by microsomal monooxygenase
enzymes of the cytochrome P4501A family (for review see 7,8),
•Abbreviations: IQ, 2-amino-3-methylimidazo{4,5-/|quinoline; NAT, N-
acetyltransferase; RFLP, restriction fragment length polymorphism; AHAT,
arylhydroxamic acid A'.O-acetyltransferase; OAT, O-acetyltransferase.
and acetyl coenzyme A-dependent arylamine A'-acetyltransferases
(NATs) in liver cytosol (9). In the case of IQ and related
heterocyclic arylamines, N-acetylation appears to be a minor
metabolic pathway (10,11). Considerable interindividual varia-
tions in the activities of these enzymes has been observed caused
either by environmental conditions or genetic polymorphisms.
P4501A1 is induced by cigarette smoking, and individuals with
genetically controlled high inducibility are at higher risk of
developing cigarette-induced bronchogenic carcinoma (12). A
restriction fragment length polymorphism (RFLP) has been
reported in the human CYP1 Al gene downstream of the coding
region (13 -15). The association of this RFLP with an increased
incidence of bronchogenic carcinoma has been observed in some
but not all populations tested (12). Point mutations in the NAT2
gene, resulting in decreased enzyme protein levels (16), are
responsible for the acetylation polymorphism, which divides the
population into so-called 'rapid' and 'slow' acetylators. Between
40 and 70% of individuals in Caucasian populations are slow
acetylators (17). Slow acetylators display impaired metabolism
of a variety of arylamine and hydrazine drugs and chemicals.
These include many therapeutically useful drugs (for review see
17,18), as well as potential arylamine carcinogens present in dyes,
antioxidants, pesticides and explosives (19).
There is circumstantial evidence for a link between rapid
acetylator status and certain diseases, e.g. colorectal cancer
(20-22). A second human NAT gene, NAT1, is not affected
by the acetylation polymorphism, and does not contribute to the
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Fig. 1. Metabolic activation of arylamine carcinogens.
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acetylator status (23,24). The availability of the cloned
NAT1/NAT2 genes allows us to test in a cell culture situation,
which one of these genes is involved, if at all, in the metabolic
activation of IQ. Upon transfection of different combinations of
NAT and CYP1A genes, P4501A2 and NAT2 resulted in the
highest IQ-DNA adduct frequencies. This suggests that the human
acetylation polymorphism may affect the carcinogenic action of
the food mutagen IQ.
Materials and methods
Chemicals
IQ was purchased from WAKO Pure Chem. Industries, Ltd (Neuss, Germany).
N-Acetyl-IQ was prepared from IQ and acetic anhydride, and was further purified
by chromatography on silica gel. Phenoxazone ethers and resorufin were purchased
from Pierce Chemicals. All other chemicals were of HPLC or analytical grade
quality and obtained from local suppliers.
Functional expression ofNATl, NAT2 CYPJA1 and CYPIA2 in monkey kidney
COS-1 cells
COS-1 cells were cultured and transfected by the DEAE-dextran/chloroquine
method as described (25). The human NAT1 and NAT2 expression constructs
in the vector p91023(B) were as described (23). cDNA clones encoding human
CYP1A1 (26) and CYP1A2 (27) were kindly provided by D.W.Nebert and
F.J.Gonzales (NCI, NIH Bethesda, MD), and were subcloned into p91023(B).
Cultures were treated with IQ or W-acetyl-IQ (dissolved in ethanol) 50 h after
transfection, and cells were harvested 9—12 h later.
Enzyme assays and detection of expressed proteins on Western blots
Enzyme activity of expressed NAT proteins was determined using sulfamethazine
as a substrate and quantitated using a HPLC assay as described (28).
P4501A1 and P4501A2 proteins in transfected COS-1 cultures and in
microsomes prepared from kidney donor liver (KDL35) were identified by
immunoreaction on Western blots with a rabbit antiserum raised against the
corresponding rat P4501A1 (P45Oc) enzyme. This antiserum recognizes both
human P4501A1 and P4501A2 proteins. Their enzymatic activities were
determined by dealkylation of phenoxazone ethers 7-methoxy- and 7-ethoxy-
resorufin as described by Burke et al. (29). Deacetylation of JV-acetyl-IQ was
measured by reversed-phase HPLC (MN 5-C18 Macherey-Nagel, Germany) by
isocratic elution using 50 mM sodium acetate/methanol (40:60) pH 6.3 as mobile
phase and UV detection at X = 254 nm.
DNA isolation and 3iP-postlabeling
Cell pellets were homogenized by means of an Ultra-Turrax, and treated with
RNase A, RNase T, and proteinase K. DNA was extracted with phenol/chlorofbrm
A B C
and precipitated with ethanol. After digestion of the DNA to 3'-nucleotides with
mjcrococcus endonuclease and spleen exonuclease (30), an aliquot of the digest
equivalent to 4 /ig was labelled with 100-120 /iCi [T - 3 2 P]ATP (sp. act. 3000
Ci/mmol; Amersham, Braunschweig, Germany) and by use of T4 polynucleotide
kinase (Pharmacia). The intensification procedure was applied according to
Randerath et aL (31). Four-directional TLC separation of the adducts was
performed on PEI-cellulose sheets (Macherey-Nagel) with the following solvents:
Dl, 1 M sodium phosphate, pH 6.8; D3, 3.8 M lithium formate, 6.8 M urea,
pH 3.4; D4, 0.6 M sodium phosphate, 0.38 M Tris-HCl, 6.5 M urea, pH 8.2;
D5, 1.7 M sodium phosphate, pH 6.0. After detection of adducts by
autoradiography, spots were excised and quantitated by Cerenkov counting;
intensification factors required for the quantitative analysis were determined in
each experiment by use of a highly IQ-modified DNA (32).
Results
Metabolic activation of IQ
Figure 1 shows the proposed enzyme reactions involved in the
metabolic activation of arylamines such as IQ. The first step of
metabolism of arylamines can either be an N-hydroxylation
(reaction 1 in Figure 1) or an N-acetylation (reaction 2 in
Figure 1). Reaction 1 may be catalyzed by either P4501A1 or
P4501A2 (7,8), and it has been shown that liver cytosolic NAT
accounts for the N-acetylation reaction (24). The A'-arylacetamide
resulting from reaction 2 serves as substrate for P4501A1 or
P4501A2, and N-hydroxylation yields the respective aryl-
hydroxamic acid (reaction 3, Figure 1). The two pathways
converge through reactions 4 (N.Otransacetylation) and 5 (O-
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Fig. 2. Immunoreaction on Western blots of CYP1A1 and CYP1A2 in
human liver microsomes and upon expression of the respective cDNAS in
COS-1 cells. Homogenates of COS-1 cells transfected with cDNAS
encoding CYP1A1 in sense (lane A) and antisense orientation (lane B), and
CYP1A2 in antisense (lane C) and sense (lane D) orientation, as well as
human liver microsomes (lane E) were subjected to SDS-PAGE (150 jig
of COS-1 homogenates and 50 fig microsomal protein), transferred to
nitrocellulose and immunoreacted with a polyclonal rabbit antiserum raised
against purified rat P4501A1.
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Fig. 3. Expressed cytochrome P4501A1 and cytochrome P4501A2 are
functionally active in COS-1 cells. Homogenates of COS-1 cells transfected
with CYP1A1 (A) and CYP1A2 (B) were incubated with methoxyresorufin
( • ) and ethoxyresorufin ( • ) , and formation of the dealkylated products
was determined at the time points indicated. Note: P4501A1 preferentially
metabolized ethoxyresorufin, whereas P45O1A2 displayed higher activity
with methoxyresorufin.
Human acetylation polymorphism
acetylation) to yield the product, N-acetoxy-A'-arylamine. Both
of these reactions have been attributed to the activity of cytosolic
NAT in hamster and rabbit (33,34), whereas no such correlation
could as yet be established for the human NAT enzymes.
Spontaneous degradation of A/-acetoxy-Ar-arylamines (reaction 6
in Figure 1) leads, presumably via unstable arylnitrenium ions
(4—6), to the formation of DNA adducts.
COS-] cell cultures provide an in vitro system to analyze IQ-
adduct formation
COS-1 cells were used to analyze the involvement of the proposed
enzymes in the above-mentioned reactions in an in vitro system,
Table I. Formation of IQ-nucleotide adducts in COS-1 cells transfected
with cytochrome P450 monooxygenase and W-acetyltransferase genes
Gene combinations Adducts/108 nucleotides (±SD)
CYP1A1
CYP1A2
NAT1
NAT2
CYP1A2
CYP1A2
+ NAT1
+ NAT2
IQ 100,1
7.3
13.6
1.7
1.6
81.6
250.3
±
±
±
±
±
±
M
0.2
2.3
0.4
0.2
5.9
28.8
IQ \0 n
ND
0
ND
ND
9.3 ±
57.2 ±
M
0
5
.7
.8
JV-Acetyl-IQ 10 /JM
ND
0
0
0
1.0 ± 0.2
14.4 ± 1.3
COS-1 cells were transfected with CYP1A1, CYP1A2, NAT1 and NAT2,
either alone or in the combination indicated. Cultures were incubated in the
presence of 10 or 100 yM IQ or W-acetyl-IQ for 12 h, followed by isolation
of the DNA and analysis of IQ-adducts.
Note: the combination of CYP1A2 and NAT2 resulted in the highest adduct
frequencies in all three experiments. Adduct formation with the acetylated
IQ substrate still required the NAT enzyme(s), indicating their inherent
N,0-transacetylase activities.
ND, not done; 0, no adducts detectable.
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Fig. 4. Identical patterns of IQ and W-acetyl-IQ adducts in COS-1 cells
expressing CYP1A2 + NAT1 and CYP1A2 + NAT2. Autoradiographs of
IQ-DNA adducts separated by TLC. (a) COS-1 cells transfected with
CYP1A2 + NAT1 (substrate: IQ, 10 /iM); (b) COS-1 cells transfected with
CYP1A2 + NAT2 (IQ. 10 nM); (c) COS-1 cells transfected with CYP1A2
+ NAT2 (substrate: JV-acetyl-IQ, 10 /iM); (d) IQ adducts formed in the
liver of a F344 rat 24 h after a 30 mg/kg oral dose of IQ; adduct frequency
123/10" nucleotides. The origin of the chromatograms is in the lower left-
hand comer.
both individually and in combination. We have previously
demonstrated that NAT1 and NAT2 can be functionally expressed
in COS-1 cells, and that COS-1 cells have no detectable
endogenous N-acerylation activity (25). In this study, we have
additionally analyzed the expression of CYP1A1 and CYP1A2
cDNAs in COS-1 cells. Immunoreaction on a Western blot of
proteins expressed from the cDNAs using a polyclonal rabbit
antiserum raised against the rat P4501A1 is shown in Figure 2.
Protein bands of the expected mol. wts of 52 and 54 kDa in
cultures transfected with CYP1A1 (lane A, Figure 2) and
CYP1A2 (lane D, Figure 2) respectively were detected. These
were indistinguishable in electrophoretic mobility from
microsomal proteins isolated from human liver (lane E, Figure 2),
suggesting that in this particular liver both P4501A proteins were
present. No immunoreactive proteins were detected in cultures
transfected with the constructs in antisense orientation (lanes B
and C, Figure 2). Cell homogenates of cultures transfected with
CYP1A1 or CYP1A2 both displayed enzyme activity with the
substrates 7-methoxy- and 7-ethoxyresorufin (Figure 3).
Homogenates of untransfected cells and cells transfected with
cDNAs in antisense orientation did not display any detectable
activities with either substrate (not shown).
The highest DNA adduct frequency occurs in COS-1 cells
transfected with CYP1A2 and NAT2
COS-1 cells were transfected with NAT and CYP1A genes
individually and in the combinations shown in Table I.
Transfected cultures were treated with IQ (at a concentration of
100 ftM) and the resulting adduct frequencies determined
(Table I, left-hand column). Transfections with NAT1 or NAT2
alone resulted in low levels of IQ-DNA adducts (1 -2 adducts/
108 nucleotides; see Table I). Slightly more DNA adducts were
found after transfection of COS-1 cells with either CYP1A1 or
CYP1A2 (7-14 adducts/108 nucleotides; Table I). From these
experiments we conclude that COS-1 cells have virtually no
endogenous enzyme activity for the acetylation and hydroxyla-
tion of arylamines. Because expressed P4501A2 was twice as
active as P4501A1, combinations of CYP1A2 and NAT genes
were used in all further experiments. As shown in Table I, these
combinations resulted in adduct frequencies 5—20 times higher
than those obtained with single genes, and NAT2 was three times
more effective than NAT1.
A lower IQ concentration (10 /tM) was applied in a second
series of transfection experiments (Table I). Qualitatively, the
same results were obtained, namely highest adduct frequencies
following transfection of CYP1A2 in combination with NAT2.
The chromatographic patterns of IQ—nucleotide adducts obtained
after activation by P4501A2 and NAT1 and by P4501A2 and
NAT2 were qualitatively identical (Figure 4a and b); the
difference was merely quantitative. The same pattern had been
found previously in liver DNA of rats that had received an oral
dose of IQ (Figure 4d), and with that obtained from the IQ-related
Table H. COS-i cells have no endogenous JV-acetyl-TQ deacetylase activity
A/-Acetyl-IQ concentration COS-1 cell homogenate Human liver
microsomes
100
200
400
0.002*
0.002
0.017*
0.085
0.232
Untransfected COS-1 cells were homogenized and assayed for endogenous
deacetylase enzyme activity using chemically synthesized JV-acetyl-IQ as
substrate. Microsomes isolated from human liver were similarly analyzed.
'Numbers represent nmol IQ/mg protein/min.
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compounds nitro-IQ in Salmonella typhimurium and azido-IQ in
calf thymus DNA (32,35). The quantitatively most prominent,
slow migrating adduct has been identified as A^-(deoxyguano-
sin-8-yl)-IQ (36).
NAT1 and NAT2 both display N,O-transacetylase (AHAT) enzyme
activity
Kinetic characterization of purified NAT enzyme activities from
rabbit and mouse liver have suggested that the same enzyme has
NAT, arylhydroxamic acid yV.Oacetyltransferase (AHAT) and
O-acetyltransferase (OAT) activities (33,34).
We used the COS-1 expression system to address the question
of whether human NATs have AHAT activity. The adduct
formation by N-acetyl-IQ was studied, which, provided that this
substrate is not deacetylated by COS-1 cells, can be converted
to an arylnitrenium ion only in the presence of AHAT activity
(Figure 1). Therefore the TV-acetyl-IQ deacetylase activity of
COS-1 cells was tested and compared with that of human liver
microsomes. As is evident from Table n, COS-1 cells display
only minute endogenous deacetylase activities at all substrate
concentrations tested, whereas significant activities were found
in human liver microsomes.
In another series of transfection experiments N-acetyl-IQ was
added to cultures and the resulting adducts were determined
(Table I). Adducts were detected with combinations of CYP1A2
and either NAT1 or NAT2. NAT2 was 14 times as effective as
NAT1, and overall frequencies were considerably lower
(1/4—1/9) than those observed with IQ at the same concentration
(10 /iM). The chromatographic pattern of the N-acetyl-IQ—DNA
adducts (Figure 4c) was the same as that of the IQ—DNA
adducts. Thus, the same arylnitrenium ion was formed from IQ
and N-acetyl-IQ and it can be concluded that both NAT1 and
NAT2 display AHAT enzyme activity. The lower adduct
frequency observed with A'-acetyl-IQ compared to that observed
with IQ is probably due to an efficient direct activation of IQ
(via N-hydroxylation and O-acetylation) and a less efficient
activation of N-acetyl-IQ (via N-hydroxylation and N,O-
transacetylation).
Discussion
In the present report we used transient expression in COS-1 cells
of each of four drug-metabolizing enzymes to study their role
in the activation of the food mutagen and carcinogen IQ. Our
experiments suggest that (i) human P4501A2 is more efficient
than P4501A1 for N-hydroxylation of this heterocyclic amine;
(ii) N-hydroxy-IQ is only weakly reactive towards DNA; (iii)
the most efficient metabolic activation and DNA adduct formation
is achieved with P4501A2 in combination with NAT2. Finally,
we propose that NAT1 and NAT2 in addition to their known
role in N-acetylation display N.O-transacetylase activity.
Our first finding is in keeping with published results obtained
in rat and rabbit. When purified rat (37) and rabbit (38) P4501A1
and P4501A2 were used in the Salmonella mutagenicity assay
with IQ, the rat P4501A2 enzyme was found to be 12 times,
and the corresponding rabbit enzyme 8 times more efficient than
P4501A1. Similarly, when mouse P4501A1 and P4501A2
enzymes were expressed in Hep G2 human hepatoma cells and
used in the Salmonella assay with IQ, P4501A2 was nine times
as active as P4501A1 (39). Thus, the available evidence points
to P4501A2 as the predominant physiological activator of IQ.
N-Hydroxylation of IQ, obtained by expression of CYP1A2 alone
(Table I), results in only minor formation of IQ-nitrenium ions
and DNA binding: an acetylation step is required as well. This
is in agreement with mutagenicity data obtained in Salmonella
1716
strains with low, normal and high acetyltransferase activity,
where the mutagenic activity of IQ (in the presence of rat liver
S9) strongly depends on the acetylator status of the strain used
(40).
The data presented indicate that the human acetylation poly-
morphism has to be considered an important factor in the
metabolic activation of arylamine carcinogens. This becomes
evident because (i) the polymorphic NAT2 in our analysis was
about five times as effective as NAT1 in activating IQ into the
arylnitrenium ion; and (ii) NAT2 possesses ten times as much
Af.O-transacetylase (AHAT) activity as NAT1, thus broadening
the spectrum of reactions affected by the polymorphism.
In addition we suggest that NAT1 and NAT2 can catalyze the
hydroxylamine O-acetylation. This was concluded from the very
low rate of IQ A/-acetylation by rodent NATs (10,41), and from
the relatively high adduct frequencies found in our IQ experi-
ments, which can only be explained by the presence of OAT
activity (see Figure 1).
In conclusion, this study provides a mechanistic basis for the
clinical observation that the acetylation polymorphism constitutes
a risk factor in the metabolic activation of environmental and
dietary mutagens/carcinogens.
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